KYMR vs. MRNA: Kymera Therapeutics vs. Moderna Stock Comparison
How do Kymera Therapeutics (KYMR) and Moderna (MRNA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Kymera Therapeutics (KYMR) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | KYMR | MRNA |
|---|---|---|
| Name | Kymera Therapeutics Inc. | Moderna Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 11.25 billion USD | 101.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | August 21, 2020 | December 7, 2018 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| Total Return (1Y) | 131.52% | 1,031.66% |
| Total Return (3Y, Annualized) | 111.65% | 58.68% |
| Total Return (5Y, Annualized) | 15.68% | 3.23% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas Kymera Therapeutics (KYMR) sees a more moderate 833.05K — larger orders in the latter may require more patience and tighter control over order sizing.
| Metric | KYMR | MRNA |
|---|---|---|
| Volatility (1Y, Annualized) | 62.83% | 194.88% |
| Beta (5Y) | 2.00 | 1.08 |
| Max Drawdown (5Y) | -83.27% | -93.93% |
| Avg. Volume (3M) | 833.05K | 21.61M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| Sharpe Ratio (1Y) | 2.03 | 5.27 |
| Sortino Ratio (1Y) | 4.16 | 20.44 |
Profitability
ROE (TTM)
Both Kymera Therapeutics (KYMR) at -27.29% and Moderna (MRNA) at -39.00% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-27.29%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- KYMR
- -27.29%
- Q1
- -64.05%
- Min
- -167.77%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-39.00%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- MRNA
- -39.00%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- KYMR
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-141.43%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- MRNA
- -141.43%
Operating Margin (TTM)
Both Kymera Therapeutics (KYMR) at -396.04% and Moderna (MRNA) at -557.93% report negative operating margin values, usually indicating operating losses over the period.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
-396.04%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- KYMR
- -396.04%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
-557.93%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
- MRNA
- -557.93%
Profitability Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| ROE (TTM) | -27.29% | -39.00% |
| ROA (TTM) | -17.64% | -13.26% |
| Net Margin (TTM) | 0.00% | -141.43% |
| Operating Margin (TTM) | -396.04% | -557.93% |
| Gross Margin (TTM) | 0.00% | -66.02% |
Growth
Revenue Growth
Both Kymera Therapeutics (KYMR) at -16.70% and Moderna (MRNA) at -39.92% post bottom-quartile revenue growth versus peers, pointing to weaker demand or pricing momentum than typical rivals.
EPS Growth
Neither Kymera Therapeutics (KYMR) nor Moderna (MRNA) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| Revenue Growth (YoY) | -16.70% | -39.92% |
| Revenue Growth (3Y CAGR) | -5.74% | -53.30% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.13
- Max
- 25.13
- Q3
- 12.13
- KYMR
- 11.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.30
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRNA
- 2.30
- Min
- 0.10
Debt / Equity (MRQ)
Both Kymera Therapeutics (KYMR) at 0.05 and Moderna (MRNA) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.05
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- KYMR
- 0.05
- Q1
- 0.02
- Min
- 0.00
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19
- Max
- 1.42
- Q3
- 0.65
- MRNA
- 0.19
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| Current Ratio (MRQ) | 11.13 | 2.30 |
| Debt / Equity (MRQ) | 0.05 | 0.19 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither Kymera Therapeutics (KYMR) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Kymera Therapeutics (KYMR) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- KYMR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MRNA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither Kymera Therapeutics (KYMR) nor Moderna (MRNA) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- KYMR
- --
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- MRNA
- --
P/S Ratio (TTM)
Both look expensive on sales: Moderna (MRNA) at 45.55 sits in the upper P/S ratio quartile, and Kymera Therapeutics (KYMR) at 110.00 prices even higher, above its industry range.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
110.00
- KYMR
- 110.00
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.55
- Max
- 58.18
- MRNA
- 45.55
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Both Kymera Therapeutics (KYMR) at 6.96 and Moderna (MRNA) at 11.58 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.
KYMR
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.96
- Max
- 13.53
- KYMR
- 6.96
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
MRNA
Pharmaceuticals, Biotechnology & Life Sciences industry group
11.58
- Max
- 13.53
- MRNA
- 11.58
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | KYMR | MRNA |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 110.00 | 45.55 |
| P/B Ratio (MRQ) | 6.96 | 11.58 |
| Free Cash Flow Yield (TTM) | -1.46% | 0.29% |